Evidence map›Paper›PMID 36322529›Full record

ArticlePloS one2022

Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials.

Abigail A Marsh, Monica Magalhaes, Matthew Peeler, Sophie M Rose, Thomas C Darton, Nir Eyal, Josh Morrison, Seema K Shah, Virginia Schmit

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Volunteering for Infection: Participant Perspectives on a Hepatitis C Virus Controlled Human Infection Model.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abigail A MarshDepartment of Psychology, Georgetown University, Washington, DC, United States of America.
Monica MagalhaesCenter for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, United States of America.
Matthew PeelerDepartment of Mathematics, Rowan-Cabarrus Community College, Salisbury, North Carolina, United States of America.
Sophie M RoseDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Thomas C DartonDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Nir EyalCenter for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, United States of America.
Josh Morrison1Day Sooner, Claymont, Delaware, United States of America.
Seema K ShahSmith Child Health Outcomes, Research and Evaluation Center, Lurie Children's Hospital, Chicago, Illinois, United States of America.
Virginia Schmit1Day Sooner, Claymont, Delaware, United States of America.ORCID 0000-0002-9894-0505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In human challenge trials (HCTs), volunteers are deliberately infected with an infectious agent. Such trials can be used to accelerate vaccine development and answer important scientific questions. Starting early in the COVID-19 pandemic, ethical concerns were raised about using HCTs to accelerate development and approval of a vaccine. Some of those concerns pertained to potential exploitation of and/or lack of truly informed consent from volunteers. Specific areas of concern arose around individuals who may be unusually risk-seeking or too economically vulnerable to refuse the payments these trials provide, as opposed to being motivated primarily by altruistic goals. This pre-registered study is the first large-scale survey to characterize people who, early in the pandemic, expressed interest and intention to volunteer to participate in COVID-19 HCTs. We found that individuals expressing interest in SARS-CoV-2 HCTs exhibit consistently altruistic motivations without any special indication of poor risk perception or economic vulnerability. In finding that, early in the pandemic, COVID-19 HCTs were able to attract volunteers whose values align with the nature of these trials, and who are not unusually vulnerable to exploitation, this study may allay some ethical concerns about the volunteers interested in participating in such trials.

Indexed as

COVID-19SARS-CoV-2HumansMotivationPandemicsVolunteers

Identifiers

PMID36322529
PMCPMC9629635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.